Navigation Links
Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference
Date:9/16/2010

FRANKLIN, Mass., Sept. 16 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick Mooney, M.D., Echo's Chairman and Chief Executive Officer, will present at the prestigious Accredited Members, Inc. (AMI) Fall 2010 Small Cap/Micro Cap Investment Conference. The conference is scheduled for September 20-22 at the Loew's Coronado Bay Resort and Spa in San Diego, CA. Echo's presentation is scheduled for 1:50 p.m. PT on September 21, 2010.

Dr. Mooney will discuss the Company's development progress. Echo Therapeutics recently announced the successful completion of a clinical study to evaluate the ability of Prelude to ablate the skin prior to the application of OTC 4% lidocaine cream for faster-acting local dermal anesthesia. In addition, Echo recently completed the initial product development work on its Prelude SkinPrep System and the Company is now focused on completing the final steps of its regulatory advance to commercialization and leveraging its key strategic partnerships to generate product-related revenue.

The Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference is expected to feature 19 private and public presenting companies. Presentations will be made to more than 400 expected attendees, each a verified accredited investor. In addition, Echo Therapeutics will be featured on the AMI website at http://www.accreditedmembers.com, for one year.

About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.For More Information:Patrick T. Mooney, M.D.

Jeffrey Stanlis

Media: Richard SternChairman and Chief Executive Officer

Partner, Hayden IR

Stern & Co.(508) 530-0329

(602) 476-1821

(212) 888-0044
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy
2. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
3. Halozyme Therapeutics Announces Public Offering of Common Stock
4. Silence Therapeutics Issued New Patents Covering siRNA Sequences for RNA Interference Therapeutics
5. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
6. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
7. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
8. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
10. BioMarin Acquires ZyStor Therapeutics, Inc.
11. Nile Therapeutics Reports 2010 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Lianluo Smart Limited (Nasdaq: LLIT ... markets and sells medical devices and wearable sleep ... and international markets, recently attended the 2016 Guangdong ... Forum, co-hosted by the Institute of Interventional Cardiology ... Provincial People,s Hospital and Cardiology Department of Guangdong ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs ... patients must find the one that works for them. When an inventor from Suisun ... that worked and decided to share it with others. , He developed a prototype ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
Breaking Medicine News(10 mins):